Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation – the third nordic aortic valve intervention trial – NOTION-3

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation – the third nordic aortic valve intervention trial – NOTION-3. / Sabbah, Muhammad; Veien, Karsten; Niemela, Matti; Freeman, Phillip; Linder, Rickard; Ioanes, Dan; Terkelsen, Christian Juhl; Kajander, Olli A.; Koul, Sasha; Savontaus, Mikko; Karjalainen, Pasi; Erglis, Andrejs; Minkkinen, Mikko; Jørgensen, Troels; Sondergaard, Lars; De Backer, Ole; Engstrøm, Thomas; Lønborg, Jacob.

In: American Heart Journal, Vol. 255, 2023, p. 39-51.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Sabbah, M, Veien, K, Niemela, M, Freeman, P, Linder, R, Ioanes, D, Terkelsen, CJ, Kajander, OA, Koul, S, Savontaus, M, Karjalainen, P, Erglis, A, Minkkinen, M, Jørgensen, T, Sondergaard, L, De Backer, O, Engstrøm, T & Lønborg, J 2023, 'Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation – the third nordic aortic valve intervention trial – NOTION-3', American Heart Journal, vol. 255, pp. 39-51. https://doi.org/10.1016/j.ahj.2022.10.009

APA

Sabbah, M., Veien, K., Niemela, M., Freeman, P., Linder, R., Ioanes, D., Terkelsen, C. J., Kajander, O. A., Koul, S., Savontaus, M., Karjalainen, P., Erglis, A., Minkkinen, M., Jørgensen, T., Sondergaard, L., De Backer, O., Engstrøm, T., & Lønborg, J. (2023). Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation – the third nordic aortic valve intervention trial – NOTION-3. American Heart Journal, 255, 39-51. https://doi.org/10.1016/j.ahj.2022.10.009

Vancouver

Sabbah M, Veien K, Niemela M, Freeman P, Linder R, Ioanes D et al. Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation – the third nordic aortic valve intervention trial – NOTION-3. American Heart Journal. 2023;255:39-51. https://doi.org/10.1016/j.ahj.2022.10.009

Author

Sabbah, Muhammad ; Veien, Karsten ; Niemela, Matti ; Freeman, Phillip ; Linder, Rickard ; Ioanes, Dan ; Terkelsen, Christian Juhl ; Kajander, Olli A. ; Koul, Sasha ; Savontaus, Mikko ; Karjalainen, Pasi ; Erglis, Andrejs ; Minkkinen, Mikko ; Jørgensen, Troels ; Sondergaard, Lars ; De Backer, Ole ; Engstrøm, Thomas ; Lønborg, Jacob. / Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation – the third nordic aortic valve intervention trial – NOTION-3. In: American Heart Journal. 2023 ; Vol. 255. pp. 39-51.

Bibtex

@article{4197f48ba2b34484b688e5076e966d3b,
title = "Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation – the third nordic aortic valve intervention trial – NOTION-3",
abstract = "Background: Coronary artery disease (CAD) frequently coexists with severe aortic valve stenosis (AS) in patients planned for transcatheter aortic valve implantation (TAVI). How to manage CAD in this patient population is still an unresolved question. In particular, it is still not known whether fractional flow reserve (FFR) guided revascularization with percutaneous coronary intervention (PCI) is superior to medical treatment for CAD in terms of clinical outcomes. Study design: The third Nordic Aortic Valve Intervention (NOTION-3) Trial is an open-label investigator-initiated, multicenter multinational trial planned to randomize 452 patients with severe AS and significant CAD to either FFR-guided PCI or medical treatment, in addition to TAVI. Patients are eligible for the study in the presence of at least 1 significant PCI-eligible coronary stenosis. A significant stenosis is defined as either FFR ≤0.80 and/or diameter stenosis >90%. The primary end point is a composite of first occurring all-cause mortality, myocardial infarction, or urgent revascularization (PCI or coronary artery bypass graft performed during unplanned hospital admission) until the last included patient have been followed for 1 year after the TAVI. NOTION-3 is a multicenter, multinational randomized trial aiming at comparing FFR-guided revascularization vs medical treatment of CAD in patients with severe AS planned for TAVI.",
author = "Muhammad Sabbah and Karsten Veien and Matti Niemela and Phillip Freeman and Rickard Linder and Dan Ioanes and Terkelsen, {Christian Juhl} and Kajander, {Olli A.} and Sasha Koul and Mikko Savontaus and Pasi Karjalainen and Andrejs Erglis and Mikko Minkkinen and Troels J{\o}rgensen and Lars Sondergaard and {De Backer}, Ole and Thomas Engstr{\o}m and Jacob L{\o}nborg",
note = "Funding Information: This study was funded by an unrestricted grant from Boston Scientific for investigator-initiated trials and a grant from the Danish Heart Foundation (17-R116-A7697-22073). The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents. Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2023",
doi = "10.1016/j.ahj.2022.10.009",
language = "English",
volume = "255",
pages = "39--51",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

RIS

TY - JOUR

T1 - Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation – the third nordic aortic valve intervention trial – NOTION-3

AU - Sabbah, Muhammad

AU - Veien, Karsten

AU - Niemela, Matti

AU - Freeman, Phillip

AU - Linder, Rickard

AU - Ioanes, Dan

AU - Terkelsen, Christian Juhl

AU - Kajander, Olli A.

AU - Koul, Sasha

AU - Savontaus, Mikko

AU - Karjalainen, Pasi

AU - Erglis, Andrejs

AU - Minkkinen, Mikko

AU - Jørgensen, Troels

AU - Sondergaard, Lars

AU - De Backer, Ole

AU - Engstrøm, Thomas

AU - Lønborg, Jacob

N1 - Funding Information: This study was funded by an unrestricted grant from Boston Scientific for investigator-initiated trials and a grant from the Danish Heart Foundation (17-R116-A7697-22073). The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents. Publisher Copyright: © 2022 The Author(s)

PY - 2023

Y1 - 2023

N2 - Background: Coronary artery disease (CAD) frequently coexists with severe aortic valve stenosis (AS) in patients planned for transcatheter aortic valve implantation (TAVI). How to manage CAD in this patient population is still an unresolved question. In particular, it is still not known whether fractional flow reserve (FFR) guided revascularization with percutaneous coronary intervention (PCI) is superior to medical treatment for CAD in terms of clinical outcomes. Study design: The third Nordic Aortic Valve Intervention (NOTION-3) Trial is an open-label investigator-initiated, multicenter multinational trial planned to randomize 452 patients with severe AS and significant CAD to either FFR-guided PCI or medical treatment, in addition to TAVI. Patients are eligible for the study in the presence of at least 1 significant PCI-eligible coronary stenosis. A significant stenosis is defined as either FFR ≤0.80 and/or diameter stenosis >90%. The primary end point is a composite of first occurring all-cause mortality, myocardial infarction, or urgent revascularization (PCI or coronary artery bypass graft performed during unplanned hospital admission) until the last included patient have been followed for 1 year after the TAVI. NOTION-3 is a multicenter, multinational randomized trial aiming at comparing FFR-guided revascularization vs medical treatment of CAD in patients with severe AS planned for TAVI.

AB - Background: Coronary artery disease (CAD) frequently coexists with severe aortic valve stenosis (AS) in patients planned for transcatheter aortic valve implantation (TAVI). How to manage CAD in this patient population is still an unresolved question. In particular, it is still not known whether fractional flow reserve (FFR) guided revascularization with percutaneous coronary intervention (PCI) is superior to medical treatment for CAD in terms of clinical outcomes. Study design: The third Nordic Aortic Valve Intervention (NOTION-3) Trial is an open-label investigator-initiated, multicenter multinational trial planned to randomize 452 patients with severe AS and significant CAD to either FFR-guided PCI or medical treatment, in addition to TAVI. Patients are eligible for the study in the presence of at least 1 significant PCI-eligible coronary stenosis. A significant stenosis is defined as either FFR ≤0.80 and/or diameter stenosis >90%. The primary end point is a composite of first occurring all-cause mortality, myocardial infarction, or urgent revascularization (PCI or coronary artery bypass graft performed during unplanned hospital admission) until the last included patient have been followed for 1 year after the TAVI. NOTION-3 is a multicenter, multinational randomized trial aiming at comparing FFR-guided revascularization vs medical treatment of CAD in patients with severe AS planned for TAVI.

U2 - 10.1016/j.ahj.2022.10.009

DO - 10.1016/j.ahj.2022.10.009

M3 - Journal article

C2 - 36220354

AN - SCOPUS:85140977677

VL - 255

SP - 39

EP - 51

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -

ID: 370115003